FMS样酪氨酸激酶3(Flt3)重组蛋白
Recombinant FMS Like Tyrosine Kinase 3 (Flt3)
CD135; STK1; FLK2; Fms-Related Tyrosine Kinase 3; Stem Cell Tyrosine Kinase 1; FL Cytokine Receptor; Fetal Liver Kinase-2
- 编号RPA039Hu01
- 物种Homo sapiens (Human，人) 相同的名称，不同的物种。
- 来源原核表达
- 宿主E.coli
- 内毒素水平<1.0EU/µg(LAL法测定)
- 亚细胞定位Membrane; Single-pass type I membrane protein. Endoplasmic reticulum lum
- 预测分子量26.9kDa
- 实际分子量27.45kDa(差异分析请参阅说明书)
- 片段与标签Lys334~Ser543 (Accession # P36888) with
- 缓冲液成份磷酸盐缓冲液（pH7.4，含有 0.01% SKL, 1mM DTT, 5% Trehalose和Proclin300.）
- 性状冻干粉
- 纯度> 95%
- 等电点8.3
-
应用
Positive Control; Immunogen; SDS-PAGE; WB.
如果需要有生物活性的蛋白，请参见活性蛋白。 - 下载 英文说明书 中文说明书
- 规格 10µg50µg 200µg 1mg 5mg
- 价格 ¥ 1075 ¥ 2688 ¥ 5376 ¥ 16128 ¥ 40320
- 欲了解实际交易价格和更多情况，请与当地经销商联系!
-
产品包装(模拟)
-
产品包装(模拟)
-
SDS-PAGE图
-
通过ISO 9001、ISO 13485质量体系认证
序列
用法
PBS或其它。
储存
避免反复冻融。2-8°C不超过一个月，-80°C不超过12个月。
稳定性
热稳定性以损失率显示。损失率是由加速降解试验决定，具体方法如下：在37°C孵育48小时，没有显著的降解或者沉淀产生。保质期内，在适当的条件下存储，损失率低于5%。
增值服务
相关产品
| 编号 | 适用物种：Homo sapiens (Human，人) | 应用(仅供研究使用，不用于临床诊断！) |
| RPA039Hu01 | FMS样酪氨酸激酶3(Flt3)重组蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAA039Hu01 | FMS样酪氨酸激酶3(Flt3)多克隆抗体 | WB; IHC; ICC; IP. |
| MAA039Hu22 | FMS样酪氨酸激酶3(Flt3)单克隆抗体 | WB; IHC; ICC; IP. |
| SEA039Hu | FMS样酪氨酸激酶3(Flt3)检测试剂盒(酶联免疫吸附试验法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| LMA039Hu | FMS样酪氨酸激酶3(Flt3)等多因子检测试剂盒(流式荧光发光法) | FLIA Kit for Antigen Detection. |
参考文献
| 杂志 | 参考文献 |
| Frontiers in physiology | Alpha-1 Antitrypsin Prevents the Development of Preeclampsia Through Suppression of Oxidative Stress [pubmed:27303303] |
| PLoS One | Evaluation of surfactant proteins A, B, C, and D in articular cartilage, synovial membrane and synovial fluid of healthy as well as patients with osteoarthritis and … [Pubmed: 30235245] |
| Bioscience Reports | N-Acetylcysteine inhalation improves pulmonary function in patients received Liver Transplantation. [Doi: 10.1042/BSR20180858] |
| Molecular Neurobiology | Elevated levels of multifunctional surfactant proteins in cerebrospinal fluid are associated with signs of increased cerebrospinal fluid flow in cranial magnetic … [Doi: 10.1007/s12035-017-0835-5] |
| Cancers | Rationale for a Combination Therapy Consisting of MCL1-and MEK-Inhibitors in Acute Myeloid Leukemia [Pubmed: 31718075] |
留言咨询